Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 29

PMID 36982892

Authors

Sofie Haglund

Jan Soderman

Sven Almer

Affiliations

Soon will be listed here.

Abstract

Vedolizumab is efficacious in the treatment of Crohn's disease (CD) and ulcerative colitis (UC). However, a significant proportion of patients present with a non-response. To investigate whether differences in the clinical response to vedolizumab is reflected in changes in gene expression levels in whole blood, samples were collected at baseline before treatment, and at follow-up after 10-12 weeks. Whole genome transcriptional profiles were established by RNA sequencing. Before treatment, no differentially expressed genes were noted between responders ( = 9, UC 4, CD 5) and non-responders ( = 11, UC 3, CD 8). At follow-up, compared with baseline, responders displayed 201 differentially expressed genes, and 51 upregulated (e.g., translation initiation, mitochondrial translation, and peroxisomal membrane protein import) and 221 downregulated (e.g., Toll-like receptor activating cascades, and phagocytosis related) pathways. Twenty-two of the upregulated pathways in responders were instead downregulated in non-responders. The results correspond with a dampening of inflammatory activity in responders. Although considered a gut-specific drug, our study shows a considerable gene regulation in the blood of patients responding to vedolizumab. It also suggests that whole blood is not optimal for identifying predictive pre-treatment biomarkers based on individual genes. However, treatment outcomes may depend on several interacting genes, and our results indicate a possible potential of pathway analysis in predicting response to treatment, which merits further investigation.

Citing Articles

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease.

Rioux J, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C medRxiv. 2024; .

PMID: 39371119 PMC: 11451768. DOI: 10.1101/2024.09.19.24314034.

Discerning Endoscopic Severity of Inflammatory Bowel Disease by Scoping the Peripheral Blood Transcriptome.

Soderman J, Almer S Gastro Hep Adv. 2024; 3(5):618-633.

PMID: 39165421 PMC: 11330933. DOI: 10.1016/j.gastha.2024.02.009.

Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease.

Puca P, Capobianco I, Coppola G, Di Vincenzo F, Trapani V, Petito V Int J Mol Sci. 2024; 25(5).

PMID: 38474034 PMC: 10931715. DOI: 10.3390/ijms25052789.

Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populations.

Arosa L, Camba-Gomez M, Golubnitschaja O, Conde-Aranda J EPMA J. 2024; 15(1):111-123.

PMID: 38463620 PMC: 10923750. DOI: 10.1007/s13167-024-00351-x.

References

Houten S, Wanders R, Ranea-Robles P . Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(5):165720. PMC: 7146961. DOI: 10.1016/j.bbadis.2020.165720. View

Gisbert J, Chaparro M . Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2019; 14(5):694-709. DOI: 10.1093/ecco-jcc/jjz195. View

Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K . Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009; 58(12):1612-9. DOI: 10.1136/gut.2009.178665. View

Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W . Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2016; 67(1):43-52. DOI: 10.1136/gutjnl-2016-312293. View

Poplawski A, Binder H . Feasibility of sample size calculation for RNA-seq studies. Brief Bioinform. 2017; 19(4):713-720. DOI: 10.1093/bib/bbw144. View

Shi W, Ye Z, Zhuang L, Li Y, Shuai W, Zuo Z . Olfactomedin 1 negatively regulates NF-κB signalling and suppresses the growth and metastasis of colorectal cancer cells. J Pathol. 2016; 240(3):352-365. DOI: 10.1002/path.4784. View

Vallania F, Tam A, Lofgren S, Schaffert S, Azad T, Bongen E . Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. Nat Commun. 2018; 9(1):4735. PMC: 6226523. DOI: 10.1038/s41467-018-07242-6. View

Alzoghaibi M . Concepts of oxidative stress and antioxidant defense in Crohn's disease. World J Gastroenterol. 2013; 19(39):6540-7. PMC: 3801366. DOI: 10.3748/wjg.v19.i39.6540. View

Postigo A, Sanchez-Mateos P, Lazarovits A, Sanchez-Madrid F, de Landazuri M . Alpha 4 beta 7 integrin mediates B cell binding to fibronectin and vascular cell adhesion molecule-1. Expression and function of alpha 4 integrins on human B lymphocytes. J Immunol. 1993; 151(5):2471-83. View

10.

Burakoff R, Chao S, Perencevich M, Ying J, Friedman S, Makrauer F . Blood-based biomarkers can differentiate ulcerative colitis from Crohn's disease and noninflammatory diarrhea. Inflamm Bowel Dis. 2011; 17(8):1719-25. DOI: 10.1002/ibd.21574. View

11.

Schneider I, Allner C, Muhl L, Melde M, Lissner D, Mantzivi E . Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease. Transl Res. 2022; 253:8-15. DOI: 10.1016/j.trsl.2022.10.003. View

12.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

13.

Lee J, Lyons P, McKinney E, Sowerby J, Carr E, Bredin F . Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011; 121(10):4170-9. PMC: 3196314. DOI: 10.1172/JCI59255. View

14.

Elhag D, Kumar M, Saadaoui M, Akobeng A, Al-Mudahka F, Elawad M . Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int J Mol Sci. 2022; 23(13). PMC: 9266456. DOI: 10.3390/ijms23136966. View

15.

Bunker R, Bulloch E, Dickson J, Loomes K, Baker E . Structure and function of human xylulokinase, an enzyme with important roles in carbohydrate metabolism. J Biol Chem. 2012; 288(3):1643-52. PMC: 3548474. DOI: 10.1074/jbc.M112.427997. View

16.

Walmsley R, Ayres R, Pounder R, Allan R . A simple clinical colitis activity index. Gut. 1998; 43(1):29-32. PMC: 1727189. DOI: 10.1136/gut.43.1.29. View

17.

Allegretti J, Barnes E, Stevens B, Storm M, Ananthakrishnan A, Yajnik V . Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017; 62(6):1590-1596. PMC: 5661939. DOI: 10.1007/s10620-017-4549-3. View

18.

Keir M, Fuh F, Ichikawa R, Acres M, Hackney J, Hulme G . Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease. J Immunol. 2021; 207(9):2245-2254. PMC: 8525869. DOI: 10.4049/jimmunol.2100220. View

19.

Gisbert J, Chaparro M . Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. J Clin Med. 2021; 10(22). PMC: 8625924. DOI: 10.3390/jcm10225318. View

20.

Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G . Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019; 18(5):1142-1151.e10. PMC: 7196933. DOI: 10.1016/j.cgh.2019.08.030. View